Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0008370
Disease: Cholestasis
Cholestasis 		0.300 Biomarker disease CTD_human Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury. 20974703 2011
CUI: C0019193
Disease: Hepatitis, Toxic
Hepatitis, Toxic 		0.300 Biomarker disease CTD_human Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury. 20974703 2011
CUI: C0030781
Disease: Peliosis Hepatis
Peliosis Hepatis 		0.300 Biomarker disease CTD_human Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury. 20974703 2011
CUI: C1262760
Disease: Hepatitis, Drug-Induced
Hepatitis, Drug-Induced 		0.300 Biomarker disease CTD_human Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury. 20974703 2011
CUI: C3658290
Disease: Drug-Induced Acute Liver Injury
Drug-Induced Acute Liver Injury 		0.300 Biomarker disease CTD_human Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury. 20974703 2011
CUI: C4277682
Disease: Chemical and Drug Induced Liver Injury
Chemical and Drug Induced Liver Injury 		0.300 Biomarker disease CTD_human Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury. 20974703 2011
CUI: C4279912
Disease: Chemically-Induced Liver Toxicity
Chemically-Induced Liver Toxicity 		0.300 Biomarker disease CTD_human Role of fibrinogen and protease-activated receptors in acute xenobiotic-induced cholestatic liver injury. 20974703 2011
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.100 AlteredExpression disease BEFREE Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. 11585763 2001
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.100 Biomarker disease BEFREE Par-4 but not Bcl-2 was detected in the secretory epithelium of benign prostatic tumors and in primary and metastatic prostate cancers that are apt to undergo apoptosis. 9989812 1999
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.100 Biomarker disease BEFREE This review discusses salient features of molecules such as, Bcl-2, Bcl-(XL), NF-kappaB, Akt, PTEN and Par-4 that play a significant role in the regulation of prostate cancer and focuses on the prospects of effectively utilizing their potential for the therapy of hormone-sensitive and hormone-resistant prostate cancer. 14965337 2004
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.100 Biomarker disease BEFREE These results establish the cooperation between Par-4 and PTEN as relevant for the development of prostate cancer and implicate the NF-kappaB pathway as a critical event in prostate tumorigenesis. 19470463 2009
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.100 AlteredExpression disease BEFREE The primary form of therapy for prostate cancer is androgen ablation resulting in apoptosis and expression of apoptotic genes (i.e. par-4). 14767530 2004
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.100 Biomarker disease BEFREE AKT inhibition and Par-4 induction suppressed prostate cancer progression in preclinical models. 28494348 2017
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.100 Biomarker disease BEFREE Par-4 for molecular therapy of prostate cancer. 12643472 2003
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.100 Biomarker disease BEFREE Par-4 deficiency cooperates with PTEN haploinsufficiency in prostate cancer initiation and progression and their simultaneous inactivation, in addition to enhancing Akt activation, sets in motion a unique mechanism involving the synergistic activation of NFkappaB. 19625770 2009
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.100 Biomarker disease BEFREE PAR4, the most recently identified PAR member, was reported to be overexpressed during the progression of colon and prostate cancers. 21635966 2011
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.100 Biomarker disease BEFREE Par-4 inducible apoptosis in prostate cancer cells. 14755681 2004
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.080 Biomarker disease BEFREE This review discusses salient features of molecules such as, Bcl-2, Bcl-(XL), NF-kappaB, Akt, PTEN and Par-4 that play a significant role in the regulation of prostate cancer and focuses on the prospects of effectively utilizing their potential for the therapy of hormone-sensitive and hormone-resistant prostate cancer. 14965337 2004
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.080 Biomarker disease BEFREE Par-4 deficiency cooperates with PTEN haploinsufficiency in prostate cancer initiation and progression and their simultaneous inactivation, in addition to enhancing Akt activation, sets in motion a unique mechanism involving the synergistic activation of NFkappaB. 19625770 2009
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.080 AlteredExpression disease BEFREE Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. 11585763 2001
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.080 Biomarker disease BEFREE Par-4 for molecular therapy of prostate cancer. 12643472 2003
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.080 Biomarker disease BEFREE AKT inhibition and Par-4 induction suppressed prostate cancer progression in preclinical models. 28494348 2017
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.080 Biomarker disease BEFREE These results establish the cooperation between Par-4 and PTEN as relevant for the development of prostate cancer and implicate the NF-kappaB pathway as a critical event in prostate tumorigenesis. 19470463 2009
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.080 AlteredExpression disease BEFREE The primary form of therapy for prostate cancer is androgen ablation resulting in apoptosis and expression of apoptotic genes (i.e. par-4). 14767530 2004
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.080 Biomarker disease BEFREE Par-4 inducible apoptosis in prostate cancer cells. 14755681 2004